{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Parkinson+Disease+3&page=2", "query": { "condition": "Parkinson Disease 3", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Parkinson+Disease+3&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T05:02:21.233Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05239728", "title": "A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Renal Cell" ], "interventions": [ { "name": "Belzutifan", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1800, "start_date": "2022-03-15", "completion_date": "2029-09-28", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-05-22T05:02:21.233Z", "location_count": 37, "location_summary": "Phoenix, Arizona • Duarte, California • La Jolla, California + 31 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05239728" }, { "nct_id": "NCT03922711", "title": "A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Parkinson Disease" ], "interventions": [ { "name": "Pridopidine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prilenia", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "30 Years to 85 Years" }, "enrollment_count": 23, "start_date": "2019-05-22", "completion_date": "2020-07-22", "has_results": true, "last_update_posted_date": "2022-07-01", "last_synced_at": "2026-05-22T05:02:21.233Z", "location_count": 33, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03922711" }, { "nct_id": "NCT04095793", "title": "Phase 3 Open-Label Extension Study of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Symptomatic Neurogenic Orthostatic Hypotension" ], "interventions": [ { "name": "ampreloxetine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Theravance Biopharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": null, "sex": "ALL", "summary": "30 Years and older" }, "enrollment_count": 110, "start_date": "2019-09-19", "completion_date": "2021-11-12", "has_results": true, "last_update_posted_date": "2022-11-30", "last_synced_at": "2026-05-22T05:02:21.233Z", "location_count": 13, "location_summary": "Colorado Springs, Colorado • Boca Raton, Florida • Port Charlotte, Florida + 10 more", "locations": [ { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Boca Raton", "state": "Florida" }, { "city": "Port Charlotte", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Glenview", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04095793" }, { "nct_id": "NCT04895358", "title": "Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Neoplasms" ], "interventions": [ { "name": "pembrolizumab", "type": "BIOLOGICAL" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "liposomal doxorubicin", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "normal saline", "type": "DRUG" }, { "name": "dextrose", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 340, "start_date": "2021-06-18", "completion_date": "2027-12-18", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-05-22T05:02:21.233Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Monterey, California + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Monterey", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04895358" }, { "nct_id": "NCT04201093", "title": "Fixed-Dose Trial in Early Parkinson's Disease (PD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Parkinson Disease" ], "interventions": [ { "name": "Tavapadon", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "40 Years to 80 Years" }, "enrollment_count": 529, "start_date": "2019-12-13", "completion_date": "2024-06-28", "has_results": true, "last_update_posted_date": "2025-07-28", "last_synced_at": "2026-05-22T05:02:21.233Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Fountain Valley, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04201093" }, { "nct_id": "NCT02352363", "title": "Randomized Safety Study of CVT-301 Compared to an Observational Control Group", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Idiopathic Parkinson's Disease" ], "interventions": [ { "name": "CVT-301", "type": "DRUG" }, { "name": "Observational cohort", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Acorda Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "30 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "30 Years to 85 Years" }, "enrollment_count": 408, "start_date": "2015-03", "completion_date": "2017-05", "has_results": true, "last_update_posted_date": "2019-05-28", "last_synced_at": "2026-05-22T05:02:21.233Z", "location_count": 14, "location_summary": "Scottsdale, Arizona • Fountain Valley, California • Panorama City, California + 10 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Panorama City", "state": "California" }, { "city": "Sunnyvale", "state": "California" }, { "city": "Ormond Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02352363" }, { "nct_id": "NCT05934747", "title": "Aim 3 Particle Swarm Optimization PIGD", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Parkinson's Disease and Parkinsonism" ], "interventions": [ { "name": "DBS", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 30, "start_date": "2024-03-19", "completion_date": "2030-01-05", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-05-22T05:02:21.233Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05934747" }, { "nct_id": "NCT04662710", "title": "Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced/Metastatic Gastroesophageal Adenocarcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Lenvatinib", "type": "BIOLOGICAL" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Leucovorin (or Levoleucovorin)", "type": "DRUG" }, { "name": "5-FU", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 895, "start_date": "2020-12-30", "completion_date": "2026-03-30", "has_results": true, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-05-22T05:02:21.233Z", "location_count": 12, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Louisville, Kentucky + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04662710" }, { "nct_id": "NCT04380636", "title": "Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Neoplasms", "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Olaparib", "type": "DRUG" }, { "name": "Placebo for olaparib", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Thoracic Radiotherapy", "type": "RADIATION" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 870, "start_date": "2020-07-06", "completion_date": "2029-07-06", "has_results": false, "last_update_posted_date": "2026-05-15", "last_synced_at": "2026-05-22T05:02:21.233Z", "location_count": 33, "location_summary": "Mobile, Alabama • Jonesboro, Arkansas • Fullerton, California + 28 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Jonesboro", "state": "Arkansas" }, { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04380636" }, { "nct_id": "NCT04003636", "title": "Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Biliary Tract Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1069, "start_date": "2019-09-24", "completion_date": "2025-04-01", "has_results": true, "last_update_posted_date": "2026-03-24", "last_synced_at": "2026-05-22T05:02:21.233Z", "location_count": 18, "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 14 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04003636" } ] }